{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-induced+Nausea+and+Vomiting+%28CINV%29&page=2", "query": { "condition": "Chemotherapy-induced Nausea and Vomiting (CINV)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-induced+Nausea+and+Vomiting+%28CINV%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-induced+Nausea+and+Vomiting+%28CINV%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T12:08:58.791Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03403712", "title": "A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "fosnetupitant/ palonosetron", "type": "DRUG" }, { "name": "netupitant/palonosetron", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 404, "start_date": "2018-03-16", "completion_date": "2018-09-19", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 36, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03403712" }, { "nct_id": "NCT00636805", "title": "Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Palonosetron (Aloxi) and Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-05", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-04-01", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00636805" }, { "nct_id": "NCT00642512", "title": "Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "dronabinol", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "dronabinol/ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solvay Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2003-07", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2008-04-03", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 43, "location_summary": "Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642512" }, { "nct_id": "NCT00787566", "title": "Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-Induced Nausea and Vomiting" ], "interventions": [ { "name": "Intranasal granisetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shin Nippon Biomedical Laboratories, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-07-12", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 1, "location_summary": "The Study Is Managed by Kendle International, in Wilmington, North Carolina", "locations": [ { "city": "The Study Is Managed by Kendle International, in Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787566" }, { "nct_id": "NCT02106494", "title": "A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "APF530", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Ondansetron placebo", "type": "DRUG" }, { "name": "APF530 placebo", "type": "DRUG" }, { "name": "Fosaprepitant", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heron Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "87 Years", "sex": "ALL", "summary": "18 Years to 87 Years" }, "enrollment_count": 942, "start_date": "2014-03", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Downey, California • Riverside, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Mishawaka", "state": "Indiana" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106494" }, { "nct_id": "NCT03204279", "title": "PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting (CINV)" ], "interventions": [ { "name": "Netupitant", "type": "DRUG" }, { "name": "Palonosetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 67, "start_date": "2017-08-31", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 5, "location_summary": "Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03204279" }, { "nct_id": "NCT00895245", "title": "Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea and Vomiting", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "fosaprepitant dimeglumine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "palonosetron hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Functional Living Index-Emesis Questionnaire", "type": "OTHER" }, { "name": "Emesis Diary", "type": "BEHAVIORAL" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "BEHAVIORAL", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2009-02", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-05-18", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895245" }, { "nct_id": "NCT04592198", "title": "Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea With Vomiting Chemotherapy-Induced" ], "interventions": [ { "name": "Palonosetron Hydrochloride Buccal Film 0.25 Mg", "type": "DRUG" }, { "name": "Palonosetron Hydrochloride Buccal Film 0.5 Mg", "type": "DRUG" }, { "name": "Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xiamen LP Pharmaceutical Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-10-01", "completion_date": "2021-03-25", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 7, "location_summary": "Anaheim, California • Ocala, Florida • Skokie, Illinois + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Hattiesburg", "state": "Mississippi" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592198" }, { "nct_id": "NCT06065722", "title": "Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "Akynzeo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Simon Williamson Clinic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-09-09", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 1, "location_summary": "Mount Olive, Alabama", "locations": [ { "city": "Mount Olive", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065722" }, { "nct_id": "NCT01442376", "title": "Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-Induced Nausea and Vomiting" ], "interventions": [ { "name": "Palonosetron", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Placebo to Ondansetron", "type": "DRUG" }, { "name": "Placebo to Palonosetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "16 Years", "sex": "ALL", "summary": "Up to 16 Years" }, "enrollment_count": 502, "start_date": "2011-09", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-08-07", "last_synced_at": "2026-10-13T12:08:58.791Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01442376" } ] }